Biocon buys back GE holding in IPO-bound Syngene
GE Capital has divested its 7.69% holding in Biocon's research services arm, Syngene International – a unit which the Indian biopharmaceutical company hopes to take public.
GE Capital has divested its 7.69% holding in Biocon's research services arm, Syngene International – a unit which the Indian biopharmaceutical company hopes to take public.